ArticleFrontiers in public health2026
Esophageal cancer mortality in China, 2008-2021: trends, disparities, and projections.
Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Using national mortality surveillance data, this study aimed to characterize temporal trends and population disparities in esophageal cancer mortality risk and premature mortality burden in China from 2008 to 2021, thereby informing stratified prevention and control strategies. Methods: Esophageal cancer deaths were obtained from the Disease Surveillance Points (DSP) system of the Chinese Center for Disease Control and Prevention (2008-2021) and identified using ICD-10 code C15. We calculated the crude mortality rate (CMR), age-specific mortality rate, age-standardized mortality rate (ASMR), years of potential life lost (PYLL), and the PYLL rate (PYLLR), stratified by sex, age group, residence (urban/rural), and region (eastern/central/western China). ASMRs were estimated by direct standardization using the age structure of the 2010 Sixth National Population Census as the standard population. Joinpoint segmented regression was applied to estimate annual percent change (APC) and average annual percent change (AAPC). Group differences were assessed using chi-square tests in R. Age, period, and birth-cohort effects were examined with the US National Cancer Institute (NCI) online Age-Period-Cohort tool. An ARIMA model was fitted to the 2008-2021 ASMR time series to project ASMR trends for 2022-2036. Results: From 2008 to 2021, the ASMR of esophageal cancer in China declined from 14.39 to 7.62 per 100,000, indicating a sustained downward trend (AAPC = -4.82%). PYLLR also decreased from 0.77‰ to 0.41‰ (AAPC = -4.55%), suggesting concurrent reductions in mortality risk and premature mortality burden; however, their stratified and segmented patterns were not fully concordant. The burden was concentrated in older adults. Across the study period, ASMR and PYLLR were consistently higher in males than females and higher in rural than urban residents. Regional disparities across eastern, central, and western China narrowed over time, accompanied by shifts in relative ranking. ARIMA projections indicated that ASMR may continue to decline during 2022-2036, with increasing uncertainty over longer horizons. Conclusion: Esophageal cancer mortality risk and premature mortality burden in China decreased substantially between 2008 and 2021, yet persistent-and dynamically evolving-inequalities by sex, residence, and region remain. Future control efforts should maintain the overall downward trajectory while prioritizing high-burden populations and key areas, strengthening early detection and early treatment, and optimizing stratified resource allocation to reduce ongoing health disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.